Coherus BioSciences (NASDAQ:CHRS) has received a Complete Response Letter (CRL) from the FDA related to its Biologics License Application (BLA) seeking approval for CHS-1701, a biosimilar to Amgen's (NASDAQ:AMGN) Neulasta (pegfilgrastim).
The CRL cited the need for a reanalysis of a subset of subject samples with a revised immunogenicity assay and additional manufacturing-related process information.
The company says it will work with the agency to address the issues. Management will host a conference call this morning at 8:00 am ET to discuss the situation.
Shares are down 34% premarket on average volume.
Subscribe for full text news in your inbox